Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis

NCT05383742 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

330

Enrollment

NIH

Sponsor class

Conditions

Tuberculous Meningitis

Interventions

DRUG: Rifampicin (RIF)
DRUG: Isoniazid (INH)
DRUG: Linezolid (LZD)
DRUG: Pyrazinamide (PZA)
DRUG: ethambutol (EMB)
DRUG: Rifampicin
DRUG: Isoniazid

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)